Consensus Amgen Inc. Xetra

Stocks

AMG

US0311621009

Pharmaceuticals

Real-time Estimate Tradegate 18:19:50 30/09/2026 +03			5-day change	1st Jan Change
372.50 ^EUR	+1.26%		+4.75%	+33.43%

05:46pm	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
09-28	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT

02a731356.iGVIT_-gF7zCRix2GR_2ooqnOvl7kQ7JDOtCsxFZWvI.7hEFDanPJoX7Inwnb1uh5P_vF8sB5H2KRYUIgiEYG7vgOhk2kc5viYl1dQ~d1c2776f7a91b199498beb33af59aa25

Analysts' recommendations: Amgen Inc.

09-28	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT
09-23	Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating	MT
09-10	HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445	MT
09-08	Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says	MT
09-08	Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating	MT
09-08	BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450	MT
09-08	Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy…
09-07	Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks…
09-04	Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating	MT
08-20	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
08-19	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
08-19	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
08-18	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT
08-18	Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating	MT
08-17	Mizuho Securities Adjusts Amgen Price Target to $352 From $303	MT
08-13	Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating	MT
08-13	Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating	MT
08-10	HSBC Adjusts Price Target on Amgen to $445 From $425, Keeps Buy Rating	MT
08-07	Citigroup Adjusts Price Target on Amgen to $405 From $345, Maintains Neutral Rating	MT
08-06	Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating	MT
08-05	Bernstein Adjusts Price Target on Amgen to $345 From $335, Maintains Market Perform Rating	MT
08-05	UBS Adjusts Price Target on Amgen to $440 From $420, Maintains Buy Rating	MT
08-05	JPMorgan Adjusts Price Target on Amgen to $350 From $300, Maintains Neutral Rating	MT
08-05	Wells Fargo Adjusts Price Target on Amgen to $400 From $390, Maintains Equalweight Rating	MT
08-05	Leerink Partners Adjusts Price Target on Amgen to $395 From $355, Maintains Market Perform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+12.17%
	JOHNSON & JOHNSON					+4.37%
	ABBVIE INC.					+5.91%
	MERCK & CO., INC.					+4.29%
	ROCHE HOLDING AG					+7.46%
	NOVARTIS AG					+5.11%
	ASTRAZENECA PLC					+28.35%
	AMGEN INC.					-7.72%
	GILEAD SCIENCES, INC.					+4.87%
	Average					+7.20%
	Weighted average by Cap.					+7.93%